Multispecific antibody engineering platforms for enhancing HIV-1 neutralization breadth, potency, and therapeutic efficacy
Scientists engineered multispecific antibodies that combine fragments from different broadly neutralizing antibodies to target multiple sites on HIV-1, improving potency and breadth for prevention and treatment, with enhanced stability and potential for delivering cytotoxic agents.
Background
Human Immunodeficiency Virus type 1 (HIV-1) infection remains a significant global health challenge, often progressing to acquired immunodeficiency syndrome (AIDS). The virus’s ability to enter host cells relies heavily on its envelope glycoproteins (Env), making Env a critical target for therapeutic and prophylactic strategies. Broadly neutralizing antibodies (bNAbs) have emerged as highly promising agents due to their potential to block viral entry and clear infected cells. There is an urgent need for advanced antibody-based therapies that can effectively combat HIV-1’s inherent capacity for immune evasion and persistent infection.
However, the clinical application of individual bNAbs is hampered by the rapid evolution of viral resistance mutations. This necessitates the use of bNAb cocktails, which, while more effective, introduce complexities and higher costs in manufacturing. Furthermore, current multispecific antibody designs face limitations, including an inability to target a sufficient number of distinct viral epitopes simultaneously or encountering steric hindrance that compromises their efficacy. Alternative potent strategies, such as DNA-linked Fabs, demonstrate enhanced activity but pose significant challenges for scalable production, highlighting a critical unmet need for more versatile and manufacturable solutions.
Technology
This technology describes novel multispecific antibodies designed to combat HIV-1. These antibodies are constructed by precisely linking single-chain variable fragments (scFvs) derived from existing broadly neutralizing antibodies. Flexible glycine-serine linkers are utilized, with their lengths and orientations meticulously optimized based on structural information of the HIV-1 envelope trimer. This engineering enables the antibodies to effectively crosslink multiple parts of the viral envelope, allowing them to target distinct, non-overlapping sites such as the CD4 binding site and V3-glycan region. The approach yields bi-, tri-, and even tetra-specific formats, demonstrating significantly enhanced neutralization breadth and potency against diverse HIV-1 strains.
What sets this technology apart is its sophisticated engineering strategy that moves beyond simple antibody combinations or existing multispecific formats. Unlike conventional approaches that may face manufacturing complexities or steric limitations, this design leverages detailed structural insights to specifically optimize inter-protomer crosslinking of the viral envelope. This precise structural guidance for linker design and scFv orientation creates a single, potent molecule that achieves superior avidity and neutralization capabilities, surpassing the individual parental antibodies or their simple mixtures. This integrated targeting mechanism provides a more robust and effective antiviral agent for both treatment and prevention of HIV infection.
Benefits
- Enhanced neutralization breadth and potency against diverse HIV-1 strains compared to parental broadly neutralizing antibodies (bNAbs)
- Simultaneous targeting of multiple, non-overlapping epitopes on the HIV-1 envelope trimer, reducing viral escape potential
- Optimized inter-protomer crosslinking of the HIV-1 Env trimer via structurally guided linker design, improving avidity
- Modular design enabling bi-, tri-, and tetra-specific antibody formats for flexible therapeutic applications
- Improved pharmacokinetic properties through Fc region modifications, potentially extending antibody half-life
- Production in mammalian cells with established purification methods, facilitating scalable manufacturing
- Capability to couple multispecific antibodies to cytotoxic agents for targeted HIV-infected cell elimination
- Use of knob-into-hole technology to promote heterodimer formation and stable multispecific antibody constructs
Applications
- HIV therapeutic antibody drug development
- HIV prevention prophylactic formulations
- HIV diagnostic reagent production
- Antibody-drug conjugate HIV therapies
Additional info
Multispecific antibodies against HIV-1 are engineered by linking broadly neutralizing antibody single-chain variable fragments via optimized flexible (G4S)n linkers. These constructs target multiple non-overlapping envelope epitopes, enabling inter-protomer crosslinking of the viral trimer. This design enhances neutralization breadth and potency, validated through binding and neutralization assays, and incorporates pharmacokinetic improvements.